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Abstract Chronic obstructive pulmonary disease (COPD) is one of the leading
causes of death and disability worldwide, but before the development of
several new pharmacological treatments little could be done for COPD
patients. Recognition that these new treatments could significantly improve
the prognosis for COPD patients has radically changed clinical management
guidelines from a palliative philosophy to an aggressive approach intended to
reduce chronic symptoms, improve quality of life and prolong survival. These
new treatments have also sparked interest in COPD cost-effectiveness re-
search. Most COPD cost-effectiveness studies have been based on clinical
trial populations, limited to direct medical costs, and used standard analysis
methods such as Markov modelling, and they have usually found that newer
therapies have favourable cost effectiveness. However, new insights into the
clinical progression of COPD bring into question some of the assumptions
underlying older analyses.
In this review, we examine clinical factors unique to COPD and recent
changes in clinical perspectives that have important implications for pharm-
acoeconomic analyses. The main parameters explored include (i) the high
indirect medical costs for COPD and their relevance in assessing the societal
benefits of new therapy; (ii) the importance of acute deteriorations in COPD,
known as exacerbations, and approaches to modelling the cost benefit of
exacerbation reduction; (iii) quality/utility instruments for COPD; (iv) the
PRACTICAL APPLICATION Pharmacoeconomics 2012; 30 (10): 869-8851170-7690/12/0010-0869
Adis ª 2012 Mapel & Roberts, publisher and licensee Springer International Publishing AG. This is an open access article
published under the terms of the Creative Commons License ‘‘Attribution-NonCommercial-NoDerivative 3.0’’
(http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits non-commercial use, distribution,
and reproduction, provided the original work is properly cited and not altered.
prevalence of co-morbid conditions and confounding between COPD and
co-morbid disease utilization; (v) the limitations of Markov modelling; and
(vi) the problem of outliers.
Key points for decision makers
 Concepts about the progression and treatment of chronic obstructive pulmonary disease
(COPD) have substantially changed over the last two decades, with several implications for the
design of pharmacoeconomic studies
 Indirect medical costs are often overlooked in COPD cost analyses, but the available data
suggest that treatment benefits may be substantial for the growing number of working-age
COPD patients
 COPD exacerbations have a great impact on healthcare utilization, so the success of cost
models is largely related to their ability to describe exacerbation-related costs
 Micro-simulation and discrete-event models may have unique advantages over Markov
models in describing COPD progression
1. Introduction
Chronic obstructive pulmonary disease (COPD)
is the variable combination of emphysema and
chronic bronchitis, both of which are caused by
an enhanced chronic inflammatory response to
cigarette smoke and other inhaled noxious partic-
ulates and gases; both result in persistent expir-
atory airflow limitation that can be confirmed by
spirometry. Symptoms caused by COPD include
shortness of breath with exertion, wheezing and
chronic cough. These symptoms are insidiously
progressive but punctuated by episodes of acute
worsening known as exacerbations. The WHO
estimates that more than 3 million people die
from COPD every year, which is 5% of all deaths
globally, and in the US COPD is now the third
most common cause of death.[1-4] Although most
people diagnosed with COPD are age 65 years and
older, it is not uncommon among middle-aged
adults and thus is a leading cause of work dis-
ability in most industrial nations.[5-8]
COPD has a substantial impact on healthcare
utilization and costs. Results from the Confront-
ing COPD in North America and Europe study,
an international survey conducted in seven countries
(Canada, France, Italy, the Netherlands, Spain, the
UK and the US), showed that for six of the seven
countries, hospitalizations for COPD per 100 in-
dividuals ranged from 27 to 43 (for the seventh
country there was on average one hospitaliza-
tion per person) and emergency department visits
ranged on average for five of the seven countries
from 33 to 78 per 100 (and from 10 to 15 for the
other two); for five of the seven countries, hos-
pitalizations accounted for 52–84% of direct
COPD healthcare costs.[9] Indirect costs varied
across countries, but were found to account for a
significant portion of the societal costs of COPD
in Canada, France, the UK and the US.[9] Direct
and societal costs were highest in the US, and the
US also had the highest percentage of individuals
reporting lost productivity due to COPD.[9]
Chronic respiratory diseases are among the top
five reasons for outpatient clinic and emergency
department visits,[10] and are also among the top
ten costliest conditions in the US.[11] In 2009,
associated costs in the US from chronic respira-
tory diseases were forecast to reach $US49.9 bil-
lion in 2010, including $US29.5 billion in direct
medical cost, $US8 billion due to morbidity and
$US12.4 billion due to mortality, with the com-
position of direct costs being 44.7% hospital care,
18.6% physician services, 19.7% prescription
drugs, 4.4% home healthcare and 12.5% nursing
home care.[1]
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Even though COPD has a tremendous impact
onmorbidity, mortality and healthcare cost, until
recently there was relatively little published on
treatment cost effectiveness. That is largely due to
the fact that treatment options were very limited
and little could be done to affect the long-term
outcome of this disease other than to give sup-
plemental oxygen to those in its terminal stages.
Over the last decade new pharmaceutical treatments
have been developed that improve the long-term
prognosis for COPD patients while also reducing
their day-to-day respiratory symptoms and im-
proving their quality of life (QOL). This has brought
a fundamental change in treatment philosophy
from a palliative approach to an aggressive in-
terventional strategy with the goals of improv-
ing overall functional status, reducing respiratory
symptoms, reducing risk of acute exacerbation
events, and providing a longer and healthier
life.[12]
As pharmaceutical treatment options have in-
creased for COPD, so has interest in treatment
cost effectiveness, partly due to increased fund-
ing of studies from pharmaceutical companies.
We reviewed the US National Library of Medicine
PubMed database and the Tufts Cost-Effectiveness
Analysis Registry, and found that as of February
2012 there were approximately 76 cost-effectiveness
studies of COPD pharmaceutical treatments that
had been published since 1990 (see the appendix
in the Supplemental Digital Content [SDC], http://
links.adisonline.com/PCZ/A155). Approximately
half of the studies were based on observational data,
one-quarter were based on randomized control-
led trials (RCTs) and the remaining one-quarter
were modelling studies. The important role RCT
studies have in providing evidence of treatment
safety, efficacy and effectiveness is well known.
Modelling studies, however, have a unique role
in that they allow for further consideration of
information from multiple studies, synthesizing
information on factors relevant to disease treat-
ment and outcomes, and allowing comparison of
competing treatments across clinical, economic
and humanistic outcomes.With regard to COPD,
the predominant pharmacoeconomic model has
been the cost-effectiveness analysis, a subgroup
of which is the cost-utility analysis.
Prior to the year 2000, there were only nine eco-
nomic evaluations of specific COPD or chronic
bronchitis drug treatments listed in MEDLINE.
Molken and colleagues[13] noted in their 1992 re-
view that cost-effectiveness studies of COPD
pharmacotherapy were found to be ‘‘totally lack-
ing’’. Ruchlin and Dasbach[14] reported findings
from published studies from 1980 to 2000, finding
15 economic evaluations of COPD pharmaco-
therapy (all but three of which were published in
1990 or later), but did not discuss methodological
aspects of the studies.
Ramsey[15] initiated discussion of critical eval-
uation of economic studies in 2000 and then
with Sullivan[16] provided a thorough examina-
tion based on the state of COPD therapy and
economic evaluations as of 2002. Ramsey and
Sullivan,[16] in addition to emphasizing that model
parameters should be clearly stated, discussed
analysis issues related to cost distributions, the
need for co-morbidity adjustment in analyses and
inclusion of QOL outcomes. In 2006, D’Souza
and colleagues[17] published a review that exam-
ined seven studies of inhaled COPDmaintenance
treatments, focusing on how well they followed
the Drummond 10-point checklist for critical
assessment of pharmacoeconomic studies;[18] five
studies were based on RCTs and the other two
were modelling studies. The main criticisms from
this appraisal concerned the heterogeneity in
study populations and definitions of outcomes,
and the paucity of comparative analyses for rel-
evant treatment strategies since the comparison
group for all studies was placebo/usual care or
ipratropium.[17] Rutten-van Molken and Lee,[19]
also in 2006, published a brief overview of five
Markov COPD progression models that had been
published in 2004 and 2005, one of which had also
been discussed by D’Souza and colleagues.[17] All
of the models incorporated a definition of COPD
severity based on staging using American Thoracic
Society percentage of predicted forced expiratory
volume in 1 second (FEV1) criteria. The main
criticisms from Rutten-van Molken and Lee[19]
concerned the variation in model populations and
utility and disease progression estimates as well
as the ability of models to incorporate the impact
of smoking and exacerbation rates on disease
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progression, noting that key priorities for future
models should be better utility information and
better definition of outcome measures.
Starkie and colleagues[20] provided the most
comprehensive review in their critical appraisal
of 15 economic evaluations of COPD treatments
published between 1990 and 2007, adding two
more modelling studies, four RCTs and one ob-
servational study to those included in previous
reviews. Of the five decision-analysis models in-
cluded, only one utilized a societal perspective;
one was published in 1993, the others in 2004–2006.
Of the more recently published studies, three as-
sessed QOL; however, health state utility values
differed greatly between studies as did the dura-
tion of effect assigned to each exacerbation.[20]
Starkie and colleagues[20] also emphasized that
the internal and external validity of models was a
major concern, as was the need for models to
capture long-term effects of treatment. Ferdinands
and Mannino[21] reviewed methodologies for
assessing validity in obstructive lung disease sim-
ulation models, five of which were COPD phar-
maceutical treatment models that have been
discussed in previous reviews.[22-26] Ferdinands
andMannino[21] were encouraged by the fact that
almost all of the reviewed models incorporated
some sort of validation review, although the
methods used for assessing model validity were
inconsistent across studies. It should be noted,
however, that the most recent COPD model re-
viewed was published in 2006 and many of the
recommendations regarding standard terminol-
ogy and reporting of methodologies are not as
relevant for more recent cost-effectiveness studies
because of the emphasis pharmaceutical outcomes
research professional organizations and journals
have placed on ensuring published articles incor-
porate a comprehensive discussion of economic eval-
uation model assumptions and functionality.[27,28]
We were able to identify an additional 14 eco-
nomic modelling evaluations for COPD published
between 2006 and early 2012 (see SDC).[29-43] Bases
for the models were: Markov processes (n = 10),
Monte Carlo simulations (n = 3) and Latin hy-
percube simulations (n = 1). Staging by FEV1 was
used to model disease progression and/or assess
risk in nine of the models;[30-32,34-36,38,41-43] ex-
acerbation experience was considered in three
models in assessing future outcomes.[29,39,40]
Almost all pharmacoeconomic COPD treat-
ment models have been published in the last
decade (2004 and later), and for the most part
have been constructed around staging using per-
centage of predicted FEV1 criteria. In that time
period several large randomized clinical trials
and longitudinal cohort studies were completed
that have not only expanded information about
specific pharmacological benefits, but have also
substantially altered treatment guidelines and fun-
damentally changed the way clinicians think
about COPD.
In this review we discuss methodological issues
that continue to be rarely addressed, as well as
recent findings that have altered the clinical per-
spective of COPD and their important implica-
tions for pharmacoeconomic analyses of COPD
treatments. An extensive list of references is pro-
vided to help illustrate these nuances of COPD
economic research; however, this is not a system-
atic review of pharmacoeconomic studies. Rather,
this is a discussion of important aspects of COPD
economics that are not currently well examined in
the literature, and how recent changes in treat-
ments and guidelines may affect future analytic
approaches.
2. Chronic Obstructive Pulmonary
Disease (COPD): Costs and Perspective
Most COPD economic analyses have exam-
ined only direct medical cost (e.g. inpatient, out-
patient and prescription pharmacy costs), written
from the perspective of the payer or provider. In a
2006 review of 13 articles assessing the economic
burden of COPD, Foster and colleagues[44] found
only two that included indirect costs. In the 14
articles we have reviewed since, we also found
only two that included indirect costs.[31,36] How-
ever, the available data obtained from ‘top-down’
approaches do suggest that in COPD these other
costs are quite substantial. In the US, the Na-
tional Heart, Lung, and Blood Institute estimates
indirect cost for COPD at 44% of total costs,
which is based largely on national expenditures
for disability payments and long-term care.[44]
872 Mapel & Roberts
Adis ª 2012 Mapel & Roberts, publisher and licensee Springer International Publishing AG. Pharmacoeconomics 2012; 30 (10)
Chronic respiratory conditions are the fourth
leading cause of disability among adults in the
US,[45] and result in over $US6.35 billion of lost
productivity each year.[46] Systems for determin-
ing disability and the amounts of compensation
vary widely among industrial nations, but most
spend about 1% of their gross domestic product
on direct disability payments, and the avail-
able data demonstrate that disability caused by
COPD has a substantial societal impact on these
countries.[47]
Studies that have used a patient-level ap-
proach are rare, but are consistent with national
health expenditure data. The Confronting COPD
Survey, which was based on structured interviews
of thousands of COPD patients worldwide, esti-
mated the average indirect costs among US par-
ticipants at 27% of total societal costs.[48] The
European and Canadian surveys found that costs
due to lost productivity ranged from 5% to 67%
of the total societal costs,[9,49-54] with variability
among countries mostly due to the large differ-
ences among the demographic characteristics of
the samples. The indirect costs varied dramati-
cally with disease severity, increasing from 4 to
17 times from mild to severe stages.[9,54] The
Obstructive Lung Disease in Northern Sweden
(OLIN) survey estimated the indirect costs to be
58% of the total costs.[55] In the SIRIO (Social
Impact of Respiratory Integrated Outcomes)
study from Italy, a comprehensive assessment of
561 COPD patients that captured both direct and
indirect costs, the total cohort lost 5703 work
days over 1 year, an amount made more im-
pressive by the fact that the mean age was 70.3
years and thus more than half were either retired
or already on medical disability.[56] Another in-
ternational survey, focused on the societal impact
of COPD among working-age adults in Brazil,
China, Germany, Turkey, the UK and the US
found that among the 2426 people who com-
pleted the survey, 40% had retired prematurely,
resulting in an average loss in lifetime income of
$US316 000 (adjusted to year 2009 US dollar
values).[57] Among those still working, COPD
symptoms resulted in an annual loss of $US880
per participant from lost time at work, and an-
other 10% reported that their productivity while
at work had been limited by respiratory symp-
toms within the last week.
Very few studies have examined whether
COPD treatment can affect indirect costs. An
analysis based on one randomized clinical trial of
fluticasone propionate in 281 COPD patients
found that due to the decreased frequency of
exacerbations in the treated group, the indirect
cost savings were sufficient to offset the increased
cost for treatment.[58] A randomized clinical trial
of 74 study subjects who had previously undiag-
nosed airflow obstruction examined the clinical
and economic consequences of an inhaled corti-
costeroid, fluticasone propionate, versus pla-
cebo.[59] The mean age of the treated group was
49.9 years as compared to 44.8 years in the pla-
cebo group, and although all were proven to have
airflow obstruction by spirometry, most had mild
disease. The average number of days that a sub-
ject was unable to work or perform their normal
daily activities was 3.2 in the treated group and
11.0 in the placebo group, which translated to
indirect costs of $US225 and $US762, respect-
ively (year 1998 values). The results did not reach
statistical significance due to the small study size
and high variability in the indirect cost estimates,
but the difference more than offset the estimated
treatment cost of $US375 per year. An additional
$US18 per patient per year was saved due to re-
duced utilization of rescue medications in the treat-
ment group. Because the treated group also had
substantial reduction in chronic respiratory symp-
toms and improved overall health status, the cost
per QALY was $US13016, a favourable estimate
compared to other chronic disease therapies.
The recent large clinical trials for salmeterol/
propionate combined (TORCH [TOwards a Rev-
olution in COPD Health])[60] and for tiotropium
bromide (UPLIFT [Understanding Potential Long
Term Impact on Function with Tiotropium])[61]
had sufficient patients for sub-analyses that con-
firmed treatment efficacy among participants
with milder COPD or individuals of working age,
including reduction in the frequency of exacerba-
tions. Although the information about the im-
pact of newer treatments on indirect costs is still
relatively rare, the available data suggest that
maintenance and preventive treatments for COPD
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can have substantial indirect cost benefits even in
populations where the direct medical costs are
only likely to increase.
3. The Importance of Exacerbations
The natural history of COPD is that of a con-
dition that slowly progresses over many years,
and because few adults regularly push their lung
function to maximum capacity, most COPD pa-
tients are asymptomatic until they have perma-
nently lost 20% or more of their lung function.
General population studies such as the Nation-
al Health and Nutrition Examination Survey
(NHANES) III have found that more than 50%
of those with significant airflow obstruction are
unaware they have a lung disease.[62] Many pa-
tients are not diagnosed until they have an acute
exacerbation event, which is usually precipitated
by acute bronchitis or pneumonia, although
many exacerbations have no identifiable aetiol-
ogy. In our study of 6864 COPD patients from
one integrated for-profit healthcare system in the
southwestern USA, we found that approximately
two-thirds were initially diagnosed during an acute
exacerbation, and 18% were diagnosed during a
hospitalization.[63]
An exacerbation event is the most common
reason for hospitalization of COPD patients,
who on average have an annual risk for hospita-
lization that is two to three times that of age- and
gender-matched controls without COPD.[63,64] In
a nationwide survey of 602 US hospitals, exacer-
bations cost an average of $US647 for an emergency
department visit, $US7242 for a simple 4-day
admission, $US20 757 for a complex admission,
and intensive care services were the most costly at
$US44 909 (year 2008 values).[65] In the UK ap-
proximately 54% of the direct medical costs for
COPD are attributable to hospitalizations,[66]
which is similar to the US estimate of 45%.[1]
Exacerbations may be relatively mild and re-
sult in only minor increases in respiratory symp-
toms, or they can be life-threatening by causing
respiratory failure or precipitating cardiovascular
complications such as acute coronary syndrome
or ischaemic stroke.[67] Most exacerbations pass
in a few days with only minor and reversible im-
pact, but some exacerbations may result in a
permanent loss of lung function so that a patient
never fully recovers to their pre-hospitalization
health status.[68] Because of the great variability
in symptoms, severity and complications, the
definition of a COPD exacerbation, not surpris-
ingly, is a subject of controversy, with calls for a
standardized definition followed by consensus
opinions, criticism of these opinions, articles on
the merits of various systems, and then more calls
for standardized definitions.[68-70]
Fortunately, for the purposes of most pharma-
coeconomics research, we are interested primarily
in how exacerbations affect healthcare utiliza-
tion, so one of the earlier and simpler consensus
definitions of exacerbations and exacerbation
severity works rather well.[71] Mild exacerbations
are characterized by an acute and sustained
worsening of the patient’s respiratory symptoms
beyond normal day-to-day variations that result
in an increased need for medication, but can be
managed in the patient’s own normal environ-
ment. Moderate exacerbations are those that are
severe enough for the patient to seek medical at-
tention in an outpatient setting such as a clinic,
urgent care office or emergency centre, plus receive
additional medications such as antibacterials or
oral corticosteroids. Severe exacerbations are
those that result in hospitalization. Certainly this
is not a perfect system – it does not account for
differences among patients in healthcare-seeking
behaviour, limitations in access to healthcare, or
variability among providers in diagnosis and
treatment. However, it does reflect an important
stratification in healthcare costs that is verifiable
and useful: mild exacerbations have minimal im-
pact on directmedical costs,moderate exacerbations
have modest but measurable direct and indirect
medical costs, and severe exacerbations are in-
evitably expensive. It is also predictable: in our
recent analysis that used the natural history of
exacerbations within relatively small cohorts to
estimate the cost benefit of newerCOPD treatments,
we found that moderate and severe exacerbations
defined by this system could be predicted with
very good precision.[39]
It was only recently recognized that COPD
exacerbations can be prevented. Following the
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introduction of long-acting bronchodilators such
as the long-acting b-agonists (formoterol, salme-
terol, indicaterol) and anticholinergic agents
(tiotropium bromide), clinicians began to realize
that those regularly using these inhaled treat-
ments were having substantially fewer exacerba-
tion events. Inhaled corticosteroids, which are of
questionable benefit in terms of their ability to
preserve lung function, were nonetheless proven
to be of value in reducing the risk for exacerba-
tions.[72] While it has been very difficult to prove
that inhaled treatments alter the accelerated de-
crease in lung function or improve survival in
COPD, the realization that regular maintenance
therapy with these long-acting inhaled agents
could reduce the risk for exacerbations resulted
in a rapid evolution in COPD treatment guide-
lines. Long-acting bronchodilators are now the
recommended first-line treatment for all people
with moderate or worse COPD.[12] Depending on
the treated population and the combination of
treatments, the newer therapies of tiotropium
bromide and fluticasone propionate/salmeterol
have been shown to produce a relative risk reduc-
tion for exacerbations ranging from 25% to 66%.[73]
The fact that some COPD treatments reduce
exacerbation events, including expensive hospi-
talizations, raises the possibility that these treat-
ments result in utilization reductions that may
partially or completely offset the cost of these
new therapies.[74,75] Even a reduction in moderate
exacerbations can produce substantial cost off-
sets, particularly among patients who have two or
more exacerbations per year. Therefore, reduc-
tion in exacerbations is a useful benefit to target
in cost-effectiveness modelling and can be a tan-
gible outcome for calculating incremental cost-
effectiveness ratios (ICERs).[39,75] Recent analyses
by Aaron and colleagues[76] have examined sta-
tistical methods for modelling exacerbation events,
and have found that threshold regression techniques
based on either a Poisson process or a Wiener
diffusion process can be used to model the natural
history of exacerbation events in a COPD treatment
cohort with very good accuracy.
The recent appreciation for the importance of
exacerbations in the pathogenesis in clinical out-
comes of COPD has led to the description of an
‘exacerbation phenotype’, or people prone to
having two or more exacerbations per year irre-
spective of their level of baseline lung function
impairment. The traditional paradigm of staging
COPD by the severity of airflow obstruction is
useful and well validated,[77] and has been the
foundation of most COPD economic evaluations,
but it also has many notable limitations. It is not
uncommon to find people with severe airflow ob-
struction who are relatively asymptomatic, phys-
ically active and otherwise healthy, and others
with mild to moderate obstruction who are dis-
abled by their pulmonary symptoms and chronic
co-morbidities. The ECLIPSE (Evaluation of
COPD Longitudinally to Identify Predictive Sur-
rogate Endpoints) study was designed to help re-
examine some of the clinical manifestations and
endpoints in COPD and identify their biological
markers.[78] Using a cohort of 2138 patients, the
ECLIPSE study identified a ‘frequent exacerbator’
phenotype, defined as people who have two or
more COPD exacerbations within a year.[79] As
expected, frequent exacerbations increase with
the severity of airflow obstruction (22%, 33% and
47% among Global Initiative for Chronic Ob-
structive Lung Disease [GOLD] stage 2, 3 and 4,
respectively). Because stage 2 COPD patients are
far more prevalent than stage 3 or 4, it is likely
that most exacerbations in the general population
occur among those with relatively moderate air-
flow obstruction. In fact, that was observed in
one hospital-based study in Spain, where 54% of
patients hospitalized for the first time for an ex-
acerbation of COPD had GOLD stage 1 or 2 at
baseline.[80] The ECLIPSE study is one of several
ongoing projects that are identifying and vali-
dating novel clinical phenotyping and prognostic
systems.
As a clinical outcome for examining cost effec-
tiveness, exacerbations may be more interpretable
to those with knowledge of COPD than QALYs.
Exacerbations are events that both patients and
physicians can easily identify and relate to, while
QALYs are an abstract construct that may be
difficult to assess, and for which underlying utility
values have varied greatly.[20,81] However, patients
who have experienced exacerbations may be able to
quantify what it is worth to them to avoid future
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exacerbations and, in fact, Rutten-van Molken
and colleagues[81] are the latest to investigate
this potential relationship in their time trade-off
valuations.
4. Cost Utilities in COPD: Quantity
of Quality
While exacerbation events are useful mea-
sures of efficacy and outcome in COPD, they are
difficult to compare with outcomes of other
chronic diseases. Cardiovascular disease also has
acute events (acute coronary syndrome, angina
attacks, arrhythmias) that make useful clinical
endpoints, but it is difficult to say that a COPD
exacerbation is equivalent to a ‘heart attack’,
especially when the severity of either is so highly
variable. In order to compare the cost effective-
ness of COPD treatment to the cost effectiveness
of other standard therapies, we need standard
units of health impact that are consistent across
diseases and disease states. The need for deci-
sion makers to have comparability in order to
allocate scarce healthcare resources has been
previously highlighted,[16,20] and we reiterate the
point here.
QALYs are very useful measures for describ-
ing treatment value. QALYs, the measurement of
utilities multiplied by time periods to create years
of varying QOL that are summated over time,
describe the amount of optimal quality time that
is gained or lost. Utility instruments are devel-
oped by asking patients to state their relative pref-
erence for a range of health states along a scale
from 0 (death or least desirable health) to 1.0 or
100 (perfect or ideal health). The negative impact
of an event such as a COPD exacerbation on
overall health, or the positive impact of a new
treatment that prevents this decrease or improves
health, can then be quantified on this scale. The
cost effectiveness of a new COPD treatment can
thus be described as the cost of the new treatment
per QALY, which can then be compared to the
cost-per-QALY of a cardiovascular treatment,
cancer treatment or any other disease where that
instrument has been validated. There are two
methods for calculating QALY utility scores: di-
rect preference measurement (e.g. standard gam-
ble, time trade-off) and using a health-related
QOL (HR-QOL) survey. The former method
is time and resource intensive, optimally using
face-to-face interviews. Consequently, the latter
method of using HR-QOL surveys is more com-
monly used.
There are currently two well validated QALY
instruments for COPD: the Quality of Well Being
Scale (QWB) and the EQ-5D. The QWB was de-
veloped byKaplan and others[82] at the University
of California – San Diego (San Diego, CA, USA)
in the 1970s as a general health status instrument,
but COPD was one of the first chronic diseases
examined to prove that the QWB was also sensi-
tive to changes in health status within one chronic
disease area. Since then it has been validated in
large clinical studies including the NETT (the
National Emphysema Treatment Trial).[83,84] The
QWB has also been demonstrated to have ex-
cellent sensitivity to changes that are the result of
COPD interventions,[85,86] have good correlation
with COPD-specific QOL instruments[86] and be
a predictor of survival.[87] The QWB was also
used to estimate the cost per QALY in NETT.[88]
Unfortunately, the QWB has rarely been used to
calculate the cost per QALY otherwise, and the
limited number of studies that have directly com-
pared the QWB with other general health status
instruments have found substantial variability
among them.[89] The QWB also has the disad-
vantage of being a much longer questionnaire: it
requires about 11minutes to administer the QWB
by phone, as compared with about 2 minutes for
the EQ-5D.[90]
The EQ-5D is a simple instrument that assesses
basic limitations (no problems, some problems or
extreme problems) in five dimensions (mobility,
self-care, usual activity, pain/discomfort and
anxiety/depression). Although it was developed
in Europe, US preference weights have been cal-
culated in a nationwide survey of more than 4000
adults.[91] Largely because of the shorter admin-
istration time and the increased emphasis in
Europe on demonstrating the cost effectiveness
of new treatments, the overall number of pub-
lished studies using the EQ-5D is far greater than
for the QWB, including those that are specific to
COPD.[57] The performance characteristics of the
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EQ-5D were described and validated in COPD in
large studies from several countries.[92-96] The
EQ-5D has shown good responsiveness to mod-
erate COPD exacerbations,[97] and in one large
epidemiological study in Spain, the EQ-5D was
able to detect the health impact of a relatively
minor and controversial defect in airflow obstruc-
tion.[98] However, the ceiling effect is a known
limitation of the EQ-5D,[99] and in a study of the
effects of a pulmonary rehabilitation programme
the ceiling effect appeared to limit the respon-
siveness.[100] Nevertheless, the EQ-5D has in-
creasingly been employed to calculate the cost per
QALY of newer COPD treatments.[35,41,42,101-104]
Because psychometric instruments tend to gain
credibility with use, and because the National
Institute for Health and Clinical Excellence tends
to accept the EQ-5D as a valid tool for assessing
QALYs, the EQ-5D will most likely continue to
grow in its dominance as the preferred instrument
for describing overall health status and QALYs
in COPD.
A concern about these standard QALY in-
struments is that they may underestimate the im-
pact that short but severe exacerbation events may
have on long-term QALYs. To address this prob-
lem, Rutten-van Molken and colleagues[81] devel-
oped 16 distinct COPD health profiles and then
surveyed 239 patients to value them using visual
analogue scales and time trade-off methods.
Their intriguing work confirms that COPD pa-
tients have reduced utility scores for periods long
after most airflow has returned to normal, and
that health profiles are a useful way to more ac-
curately capture the varied health states asso-
ciated with COPD exacerbations.[81]
5. The Importance of Co-Morbidities
Approximately 80% of COPD cases worldwide
are attributable to cigarette smoking, and the
proportion is probably higher in countries where
woodstoves and biomass are not used for cooking
and indoor heating. Cigarette smoking and in-
halation of other carbon-based particulates cause
a wide variety of health effects beyond COPD,
leading to co-existing morbidities that can have a
confounding or additive effect on COPD utiliza-
tion. Case-control analyses show that COPD pa-
tients have increased utilization in almost every
disease category, but most especially in those
categories directly attributable to cigarette smok-
ing such as lung cancer and cardiovascular dis-
ease.[64,105,106] Additionally, some diseases that
are not as commonly associatedwith cigarette smok-
ing, such as gastric ulcers and dyspepsia, are none-
theless substantially increased in COPD.[64,105,107]
Large prospective clinical trials and cohort
studies help demonstrate the impact of co-
morbidities in COPD. The LHS (Lung Health
Study) was a randomized clinical trial of smoking
cessation and inhaled ipratropium therapy in
5887 smokers with mild to moderate COPD. Over
14.5 years of follow-up, lung cancer was the most
common cause of death among LHS participants
(n = 240 [33% of all deaths]), followed by cardio-
vascular diseases (n = 163 [22%]) and cancer of
organs other than the lungs (n = 154 [21%]), with
respiratory non-cancer deaths relatively uncom-
mon (n = 57 [8%]).[108] In the TORCH study, the
probability of having a cardiovascular adverse
event over the 3 years of follow-up ranged from
20.8% to 24.3%, which was not significantly dif-
ferent among the four treatment arms but higher
than the probability of having pneumonia (12.3–
19.6%).[109,110] In an analysis of 1986 people who
had lung function testing as part of the population-
based OLIN survey in Sweden, those with mild
COPD had a substantially increased prevalence
of diagnosed cardiovascular disease (48%) as
compared with similar people with normal lung
function (41%), and increased to 53% for those
with stage II COPD.[107] Smoking cessation is
undoubtedly the most cost-effective intervention
among those COPD patients who are still smoking,
largely due to the reduction in co-morbidities.
Even in the LHS where only 11% of patients
were able to achieve complete abstinence from
cigarettes at 12 months, those who were able to
quit have significantly improved all-cause survi-
val, mostly due to the reduction in cardiovascular
diseases.[108]
Safety data from randomized clinical trials
suggest that newer COPD treatments can reduce
the risk of some co-morbidities, including major
cardiovascular events, although the available data
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are limited because individuals withmultiple chronic
conditions are under-represented in randomized
clinical trials.[111] In a pooled analysis of clinical
trials, users of tiotropium bromide had a 17%
reduction in major cardiovascular events, and
23% reduction in fatal cardiovascular events,
versus placebo (p < 0.05 for both).[112] Cardiovas-
cular events were reduced by 14% among users of
salmeterol/fluticasone combined versus placebo
in the 3-year TORCH study.[110] In clinical trials
for indacaterol, a long-acting once-a-day inhaled
b-agonist, treatment was associated with con-
sistently lower cardiovascular events, although
the hazard ratio reductions did not reach statistical
significance in these short-term studies where the
event rates tend to be low.[113,114] Co-morbidity-
associated event data are very limited even in
clinical trials because they are usually captured
as adverse events and not primary or secondary
endpoints. Studies that have compared the cause
of death in the opinions of adjudication panels
with the opinions of local investigators have found
wide discrepancies.[115,116] Nevertheless, the avail-
able data suggest that therapies that reduce COPD
exacerbation events also cause beneficial reductions
in the risk for major cardiovascular events.
Estimating the cost benefits of a reduction in
co-morbidity-related events is a challenge, but
ignoring the impact of co-morbidities is likely to
result in a substantial underestimate of treatment
cost benefits. There are relatively few COPD cost
analyses that have included detailed information
on co-morbidities.[63,64,117-120] In a multifactorial
analysis of direct medical costs, we found that the
presence of co-morbidities was a stronger pre-
dictive factor for high future costs than the degree
of airflow obstruction.[119] COPD and cardiovas-
cular disease utilization are heavily confounded
due to the high prevalence of cardiovascular dis-
ease among COPD patients, the increased mor-
bidity of exacerbations among those with both
cardiovascular disease and COPD,[121] and the in-
creased risk for subsequent cardiovascular events
among those with COPD exacerbations.[67]
One approach to dealing with co-morbidities
is to simply attribute all utilization occurring
during an exacerbation to COPD, then attribute
all care occurring during other time intervals to
‘usual care’.[39] This strategy assumes that the co-
morbidity-related utilization that occurs during
an exacerbation would have been avoided had the
exacerbation also been avoided. Although this
strategy is logical and straightforward, an im-
portant limitation is that one has to make an
assumption about the average duration of an
exacerbation, and there is limited information
on how best to estimate this. One of the few cohort
studies that have prospectively examined this
issue found that the average exacerbation that
does not result in hospitalization is resolved within
a week, but approximately 25% had detectable
effects after 35 days, and 7% had still not recovered
their previous lung function at 90 days.[68] Longi-
tudinal studies that have examined total healthcare
costs before and after the initial diagnosis, which is
commonly associated with exacerbation events,
show that utilization attains a new baseline after
60 days, suggesting that 60 days should be the
maximum exacerbation interval.[63,122]
6. Markov Modelling: Tried but True?
Traditionally, COPD has been described as a
slowly progressive disease with its severity divided
into four stages ranging from one (mild obstruction
with reduction in the FEV1/forced vital capacity
ratio but FEV1 greater than 80% of predicted
value, and likely to be minimally symptomatic) to
4 (severe obstruction with FEV1 less than 30% of
predicted value, and likely to be dependent on sup-
plemental oxygen).[77] In early concepts of COPD
progression, the accelerated decline in airflow was
described as a steady linear function,[123] and when
patientsmanaged to quit smoking the rate of decline
would revert to the same normal rate of airflow
decline experienced by never-smokers. This tra-
ditional COPD concept of progression is well
suited to modelling using basic Markov model-
ling techniques and has been widely used in COPD
treatment cost-effectiveness analyses to model
transitions across stages. All but four of the model-
ling studies published in 2004 or later that we
reviewed used Markov processes (see SDC).
The concepts of pathogenesis and progres-
sion of COPD on which these traditional models
are based are being called into question.[124] Re-
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cent cohort studies have demonstrated that while
the mean group changes over time support the
Fletcher-Peto concept of progressive losses in
airflow over time, the changes in lung function
and disease states among individual COPD pa-
tients are highly variable.[125] COPD exacerbations
and other serious events can result in permanent
lung injury and change in health status, and for
affected individuals their airflow decline is more
likely to resemble a step function with sudden
declines associated with acute events against
a background of relatively slow and steady de-
cline.[126,127] Furthermore, some patients con-
tinue to have an accelerated rate of decline even
after they stop smoking,[128] which may represent
inflammatory mechanisms that continue to be
deranged long after the noxious exposure is gone.
The impact of exacerbations on lung function
appears to be heterogeneous across populations
and not always apparent depending on the pop-
ulation and study design.[129] In the most recent
version of the GOLD statement, the concept of
COPD staging has been discarded altogether.[12]
The degree of airflow obstruction is still described in
four ‘grades’, but it is specifically acknowledged
that a staging system based on FEV1 alone is in-
adequate and that evidence for an alternative
staging system does not exist.[12] Increasingly,
COPD is being understood as a disease with a
high degree of variability in exacerbation experi-
ence and disease progression, and the basis for
describing disease state transitions in COPD used
in these Markov models bears reconsideration.
As we have already noted, it was recently es-
tablished that a substantial proportion of COPD
patients have an exacerbation phenotype, and the
fundamental characteristic of this phenotype is
that the frequency of exacerbation events does
predict future outcomes.[79] While it is theoreti-
cally possible to use advanced techniques such as
tunnel states to allow integration of COPD ex-
acerbations and other events from prior cycles
to modify individual probabilities, these still in-
troduce unstable assumptions about the risk for
exacerbations, their severity and duration, and
impact on co-morbid conditions.
Using the Markov modelling approach is a very
well established and flexible technique and software
for creating Markov models is widely available.
However, there needs to be a careful reconsidera-
tion of what most accurately describes a disease
state transition in COPD and how to best model
the great heterogeneity in disease progression.
The percentage of predicted FEV1 will always be
a useful diagnostic measure for COPD, but it is a
weak correlate of most clinically relevant out-
comes, including survival.[130] Multidimensional
staging tools such as the BODE Index (which
takes into account Body mass index, airway Ob-
struction, Dyspnoea and Exercise tolerance) have
been proven to be better predictors of clinical
outcomes, but until current longitudinal studies
with these measures are completed, there is very
little long-term epidemiological information on
the natural history of COPD on which to base
comprehensive Markov models.
Recent papers have explored the appropriate-
ness of decision-tree, Markov, and discrete-event
or micro-simulation models for health-related
economic models.[131-133] Each type of model has
its advantages and disadvantages. More complex
models require more detailed information and
advanced modelling skills and often lack trans-
parency for decision makers, but they may provide
more realistic assessments of complex diseases.
Unfortunately, there are not many published ex-
amples of good alternatives to Markov models
for COPD treatments, but in health economic
evaluations of smoking cessation treatments, a
patient-level simulation model (a.k.a. Monte Carlo
micro-simulation model) has been successfully
applied to model outcomes over extended hor-
izons and validated using international epide-
miological data.[134] It is reasonable to expect that
models for smoking cessation are likely to also
work well for modelling COPD treatments, since
smoking cessation is in itself a COPD treatment,
and it shares the problem of having multiple po-
tential interventions, a wide range of outcomes
and co-morbidities, and variable treatment com-
pliance states. One compelling advantage micro-
simulation models have over Markov models is
the ability to model multiple events during a time
interval (e.g. a COPD exacerbation and a heart
attack) as well as incorporating an individual’s his-
tory of events into their probability estimates.[132]
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7. The Problem of Outliers
As we have already noted, COPD patients
have a high risk for hospitalization due to exacer-
bation and other causes. Because these events
may precipitate respiratory failure, admission to
an intensive care unit and prolonged mechanical
ventilation, it is not unusual for a number of
COPD patients to have total direct medical costs
that are more than ten times greater than average.
In a survey of COPD hospitalizations in 602 hos-
pitals from across the US, complicated admis-
sions accounted for only 5.8% of the care, but
20.9% of the total costs, and mean costs for in-
tensive care unit admissions were $US44 909 as
compared with $US7242 for simple hospital ad-
missions (year 2008 values).[65]
COPD is an example of a condition where the
distribution of the annual total direct medical cost
across a population will range from a substantial
proportion with zero cost to a handful with cost
of a half a million dollars or more. The presence in
econometric modelling of cost data with a ‘heavy’
upper tail has previously been raised as an important
issue.[135] Transformation of cost data using a log
scale is one common method of shortening a long
right tail and decreasing the influence of outliers,
but is not useful in cost-effectiveness studies in
which an ICER is assessed. Frequently, the mean
may be much greater than the median value for
most patients; however, use of a distribution statis-
tic other than the mean in calculating an ICER is
not recommended.[136] Large sample sizes are
robust to tail problems, but in a relatively small
study population the effects of even one outlier
may be very dramatic. In a cost analysis of a
clinical trial of controller therapy in 449 COPD
patients in Canada, inclusion of one individual
who had a prolonged hospitalization changed the
ICER estimate for cost per exacerbation avoided
from $US3876 to $US6510 (year 2004 values).[137]
Clearly, newer treatments can reduce the risk for
exacerbations, and there is some evidence suggest-
ing that the severity of exacerbations amongst
those still having them is decreased.[138] However,
it is not known whether these catastrophic events
that result in extremely high cost for a few in-
dividuals can be avoided.
Occasionally, outliers are related to data entry
or processing errors, and researchers using pub-
lished cost estimates rely on analysts in clinical
trials or observational studies to perform com-
prehensive reviews of data values and include
explanation of outliers in reports, but due to
space limitations, manuscripts cannot include all
study details, and potential causes of cost outliers
are rarely discussed. Until extreme outliers are
better understood, it is reasonable and advisable
to decide how outliers will be dealt with a priori as
part of the study analysis plan. For most current
models this entails performing sensitivity analy-
ses on cost assumptions.
8. Conclusions
Fortunately, the recent development of several
new treatments for COPD has changed the
overall management philosophy from a sense of
nihilism and palliative symptom management to
a more optimistic outlook and proactive ther-
apy.[139] The availability of new treatments has
also prompted an explosion of new clinical research
in this disease plus the recognition that some of
our old paradigms have serious flaws that could
not explainmany common clinical findings. As new
paradigms are developed to explain the spectrum
of clinical presentations, pathophysiology and
natural history of this disease, the approaches to
cost-effectiveness analysis will also need to adapt.
This is a welcome problem for the millions of
patients who are affected by this disease and
those who are interested in helping them.
Among patients with diagnosed COPD, the
greatest proportion of direct medical costs have
been for hospital care, most of which is directly
attributable to COPD exacerbations and co-morbid
complications. Fortunately, several of the newer
COPD treatments are proven to reduce the risk
for exacerbations that lead to hospitalization, and
thus are likely to be cost effective. However, even
among patients with milder symptomatic disease,
the impact of COPDon lost days at work and other
indirect costs make it likely that treatment is cost
effective from the societal perspective even among
those who are not being hospitalized. Direct com-
parison of the cost utility of COPD treatment with
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other chronic disease therapies is likely to demon-
strate that the newer COPD treatments are among
the most cost-effective chronic disease treatments
available, and thus might convince the clinical ni-
hilists (unfortunately, who are still not uncommon)
that COPD treatment is worth everyone’s effort.
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